Press release
Head and Neck Cancer Treatment Market Size Report 2034 | CEL-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC
Head and Neck Cancer Market
Discover Key Insights into the Head and Neck Cancer Market with DelveInsight's In-Depth Report @ Head and Neck Cancer Market Size- https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Head and Neck Cancer Market
• In February 2025:- Coordination Pharmaceuticals Inc.:- This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer. To determine the tolerability of RiMO-301 with hypofractionated X-ray radiotherapy and a PD-1 inhibitor (pembrolizumab or nivolumab) in patients with unresectable, recurrent or metastatic head-neck cancer.
• In February 2025:- Boehringer Ingelheim:- This randomized, open-label, phase III study will be performed in patients with recurrent and/or metastatic head and neck cancer which has progressed after platinum-based therapy. The objectives of this trial are to compare the efficacy and safety of afatinib versus methotrexate.
• In February 2025:- Merck Sharp & Dohme LLC:- This is a randomized, active-controlled, open-label study of pembrolizumab (Pembro) given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone.
• In February 2025:- QBiotics Group Limited:- A Phase II, open label, single arm study to assess the efficacy of intratumoural tigilanol tiglate in various head and neck solid malignancies.
• In February 2025:- Adlai Nortye Biopharma Co. Ltd:- The BURAN study is a randomized, open-label phase III study to assess the treatment effect of once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel alone in patients with refractory, recurrent, or metastatic head and neck squamous cell carcinoma (HNSCC) that have progressed after prior anti PD 1/anti PD L1 monotherapy; prior anti PD 1/anti PD L1 therapy in combination with platinum-based therapy; or after sequential treatment of anti PD 1/anti PD L1 therapy, either prior to or post, platinum-based therapy.
• As per DelveInsight analysis, Among the 7MM, the United States accounted for the largest Head and Neck Cancer market size (more than USD 2,000 million), in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan in 2023.
• As per DelveInsight's epidemiology model, the total incident cases of Head and Neck Cancer (HNC) in the 7MM was around 162,000 in 2023, and the United States showed the highest incident cases of HNC representing ~41% of total cases in the 7MM.
• Leading head and neck cancer companies such as CEL-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC, Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, Kura Oncology, Hoffmann-La Roche, Eli Lilly and Company, and others are developing novel head and neck cancer drugs that can be available in the head and neck cancer market in the upcoming years.
• The head and neck cancer therapies such as Leukocyte Interleukin (MULTIKINE), Toripalimab, Cabozantinib, Eftilagimod alpha (Efti/IMP321), LN-145 (Tumor Infiltrating Lymphocytes), Tislelizumab, Penpulimab/AK105, Tipifarnib, XEVINAPANT (Debio 1143), TECENTRIQ (atezolizumab), Cyramza (ramucirumab), and others.
Stay ahead in the Head and Neck Cancer Therapeutics Market with DelveInsight's Strategic Report @ Head and Neck Cancer Market Outlook- https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Head and Neck Cancer Epidemiology Segmentation in the 7MM
• Total Incident Cases of Head and Neck Cancer
• HPV-specific Incident Cases of Head and Neck Cancer
• Site-specific Incident Cases of Head and Neck Cancer
• Molecular Alteration-specific Incident Cases of Head and Neck Cancer
• Stage-specific Incident Cases of Head and Neck Cancer
Download the report to understand which factors are driving head and neck cancer epidemiology trends @ Head and Neck Cancer Prevalence:- https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Head and Neck Cancer Treatment Market
Chemotherapy has widely used in all lines of head and neck treatment among all available therapeutic options. Numerous drugs have been identified with the advancement of medical technologies and increased research and development activities. Immunotherapeutic options for treating HNC patients have also been identified. Overall, head and neck cancer treatment options for patients with HNC include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Pharmacological therapies are primarily used to destroy cancer cells and are administered systematically or locally (by a medical oncologist). Chemotherapy, targeted therapy, and immunotherapy are some of the pharmacological head and neck cancer treatments available to HNC patients.
To know more about head and neck cancer treatment options, visit @ New Treatment for Head and Neck Cancer- https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Head and Neck Cancer Pipeline Therapies and Key Companies
• Leukocyte Interleukin (MULTIKINE): CEL-SCI
• Toripalimab: Junshi Biosciences/Coherus
• Cabozantinib: Exelixis
• Eftilagimod alpha (Efti/IMP321): Immutep S.A.S./Merck Sharp & Dohme LLC
• LN-145 (Tumor Infiltrating Lymphocytes): Iovance Biotherapeutics
• Tislelizumab: BeiGene
• Penpulimab/AK105: Akeso/Chia Tai-Tianqing
• Tipifarnib: Kura Oncology
• XEVINAPANT (Debio 1143): Merck KGaA
• TECENTRIQ (atezolizumab): Hoffmann-La Roche
• Cyramza (ramucirumab): Eli Lilly and Company
Learn more about the head and neck cancer treatment guidelines @ Drugs for Head and Neck Cancer Treatment- https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Head and Neck Cancer Market Dynamics
The survival of head and neck cancer is steadily improving, and it is emphasized that a better understanding of tumor pathobiology will lead to better therapies and outcomes in the head and cancer market. Clinical trials are being conducted to understand better the role of HPV and the combinations of various therapies. Response rates are higher when chemotherapy is combined with PD-1 inhibitors in HPV+ tumors. These kinds of new insights will undoubtedly be useful in the future for the growth of the head and neck cancer market.
Scope of the Head and Neck Cancer Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Head and Neck Cancer Companies: CEL-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC, Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, Kura Oncology, Hoffmann-La Roche, Eli Lilly and Company, and others
• Head and Neck Cancer Therapies: Leukocyte Interleukin (MULTIKINE), Toripalimab, Cabozantinib, Eftilagimod alpha (Efti/IMP321), LN-145 (Tumor Infiltrating Lymphocytes), Tislelizumab, Penpulimab/AK105, Tipifarnib, XEVINAPANT (Debio 1143), TECENTRIQ (atezolizumab), Cyramza (ramucirumab), and others
• Therapeutic Assessment: Head and Neck Cancer current marketed and emerging therapies
• Head and Neck Cancer Market Dynamics: Head and Neck Cancer market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Head and Neck Cancer Market Access and Reimbursement
Discover more about drugs for head and neck cancer in development @ Head and Neck Cancer Clinical Trials and Advancements- https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Contents
1. Head and Neck Cancer Market Key Insights
2. Head and Neck Cancer Market Report Introduction
3. Head and Neck Cancer Market Overview at a Glance
4. Head and Neck Cancer Market Executive Summary
5. Disease Background and Overview
6. Head and Neck Cancer Treatment and Management
7. Head and Neck Cancer Epidemiology and Patient Population
8. Patient Journey
9. Head and Neck Cancer Emerging Drugs
10. Seven Major Head and Neck Cancer Market Analysis
11. Head and Neck Cancer Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Head and Neck Cancer Market Drivers
15. Head and Neck Cancer Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
List of Top Selling Market Research Reports in 2025
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/underactive-bladder-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical sealant market - https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Trichotillomania market- https://www.delveinsight.com/sample-request/trichotillomania-ttm-market
Medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Head and Neck Cancer Treatment Market Size Report 2034 | CEL-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC here
News-ID: 3894190 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Head
Green Dot Sign® Going Head-to-Head with Traditional Plastic ADA Signs
After the success of their groundbreaking sustainable ADA compliant interior signs, Green Dot Sign® is now offering a more affordable and adaptable option than ever before: Low profile office signs.
Nussbaum started considering environmentally-friendly manufacturing methods and products while working at his prior sign company. The idea to create signage from a wood base and non-toxic 3D printed material for lettering, braille, and pictograms was sparked by a braille sign with…
China and India are growing head to head in Companion Diagnostic market
“Asia-Pacific Companion Diagnostics Market" research report, published by Market Data Forecast estimates that the market is growing with a CAGR of 27.91% to reach USD 2.17 billion by 2021, from USD 0.63 billion in 2016, which amounts to a cumulative growth of USD 1.54 billion.
A companion diagnostics device is a medical device that provides information which is necessary for drug safety and effectives or any other biological product. This helps…
East and West going head to head in Asia-Pacific Food Emulsifiers Market
Asia-Pacific Food Emulsifiers Market" research report, published by Market Data Forecast delineates that the market is growing with a CAGR of 6.15% to reach USD 0.78 billion by 2021, from USD 0.58 billion in 2016, which amounts to a cumulative growth of USD 0.20 billion.
View Full Report at http://www.marketdataforecast.com/market-reports/asia-pacific-food-emulsifiers-market-564/
Download Free Sample report at http://www.marketdataforecast.com/market-reports/asia-pacific-food-emulsifiers-market-564/request-sample
A substance used in food manufacturing which helps to combine liquids of different thicknesses is known as…
dinCloud Earns Top Marks in Head-to-Head Comparison
The #1 Brand in Hosted Virtual Desktops
LOS ANGELES, CA – June 19, 2012 – dinCloud, a cloud transformation company and provider of hosted virtual desktops, has come out on top as the leading provider of DaaS (Desktop as a Service) in a head-to-head comparison of five market leaders by ExtremeLabs. dinCloud’s solution received the groupings highest marks for the solution’s good control, as well as fast response, and was the…
University Students go head to head in University of Bolton’s “Sports Fiesta …
The University of Bolton Student’s Council and the Student Activities Department organized an integrated program of sporting activities around the theme "Sports Fiesta 2012" which drew a number of Universities from the Northern Emirates and Dubai.
The activities took place at UOB RAK Campus. Separate activities for male and female attendees included; badminton, basketball, chess, cricket, darts, tug-o-war, sprint race, football and volleyball matches, and other recreational games.
To coincide with the…
KnowledgetoAction Departments Go Head to Head in a Bowling Competition
London, UK ( ) October 25, 2010 - Employees of KnowledgetoAction (http://knowledgeandaction.co.uk) have been going head to head against each other in a series of team building competitions that began on September 1, 2010. Knowledge to Action believes strongly in team building and this event showcased their desire for excellent team cooperation and communication between departments, allowing for more cohesiveness within Knowledge to Action.
Most recently, each of the KnowledgetoAction…
